Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in china: Final result of a phase II trial

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 10, 2011, Pages 2797-2800

  Huang, Xin En ^a   Li, Cheng guang ^a   Li, Yin ^a   Lu, Yan Yan ^a   Tang, Jin Hai ^a   Xiang, Jin ^a  

^a JIANGSU CANCER HOSPITAL   (China)

Author keywords

Adjuvant chemotherapy; Breast cancer; Cisplatin; Paclitaxel

Indexed keywords

EID: 84863239950     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Camoriano JK, Loprinzi CL, Ingle JN, et al (1990). Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol, 8, 1327-34.
2. Cardoso F, Atalay G, Piccart MJ (2002). Optimizing anthracycline therapy for node positive breast cancer. Am J Cancer, 1, 257-68.
3. Conte PF, Guarneri V, Bruzzi P, et al (2004). Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial. Cancer, 101, 704-12.
4. Ferlay J, Bray F, Pisani P, et al (2004). Globocan 2002: Cancer Incidence, mortality and prevalence worldwide, Version 2.0. IARC Cancer Base No. 5. Lyon, France: IARC Press.
5. Frasci G, Comella P, Parziale A, et al (1997). Cisplatin-paclitaxel weekly schedule in advanced solid tumors: a phase I study. Ann Oncol, 8, 291-3.
6. Frasci G, Comella P, D'Aiuto G, Budillon A (1998), Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study. Breast Cancer Res Treat, 49, 13-26.
7. Gelmon KA (1995). Biweekly paclitaxel in the treatment of patients with metastatic breast cancer. Semin Oncol, 22, 117-22.
8. Goodwin PJ, Ennis M, Pritchard KI, et al (1999). Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol, 17, 2365-70.
9. Henderson IC, Berry DA, Demetri GD, et al (2003). Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with nodepositive primary breast cancer. J Clin Oncolm, 21, 976-83.
10. Holmes FA, Walters RS, Theriault RL, et al (1991). Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst, 83, 1797-805.
11. Huang XE, Hirose K, Wakai K, et al (2004).Comparison of lifestyle risk factors by family history for gastric, breast, lung and colorectal cancer. Asian Pac J Cancer Prev, 5, 419-27.
12. Kaplan EL, Meier P (1958). NoTParametric estimation from incomplete observations. J Am Stat Assoc, 53, 457-81.
13. Mamounas EP, Bryant J, Lembersky B, et al (2005). Paclitaxel after doxorubicin plus cyclophosphamideas adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol, 23, 3686-96.
14. Rowinsky EK, Gilbert MR, McGuire WP (1991) Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol, 9, 1692-703.
15. Schiff PB, Fant J, Horwitz SB (1979). Promotion of microtubule assembly in vitro by taxol. Nature, 277, 665-71
16. Tolcher AW, Gelmon KA (1995). Interim results of a phase I/II study of biweekly paclitaxel and cisplatin in patients with metastatic breast cancer. Semin Oncol, 22, 28-32.
17. Wasserheit C, Frazein A, Oratz R (1996). Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J Clin Oncol, 14, 1993-9.
18. Yan PW, Huang XE, Jiang Y, et al (2010). A clinical comparison on safety and efficacy of Paclitaxel/Epirubicin (NE) with Fluorouracil/Epirubicin/Cyclophosphamide (FEC) as postoperative adjuvant chemotherapy in breast cancer. Asian Pacific J Cancer Prev, 11, 1115-8.
19. Yang L, Parkin DM, Ferlay J, et al (2005). Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev, 14, 243-50.
20. Yu KD, Di GH, Wu J, et al (2007). Development and trends of surgical modalities for breast cancer in China: A review of 16-year data. Ann Surg Oncol, 14, 2502-9.
21. Zhou JN, Huang XE, Ye Z, et al (2009). Weekly paclitaxel/Docetaxel combined with a paltinum in the treatment of advanced non-samll cell lung cancer: a study on efficacy, safety and pre-medication. Asian Pacific J Cancer Prev, 10, 1147-50.